PADMINI KAUSHAL, M.D.
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in WHEATON, Illinois. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
PADMINI KAUSHAL, M.D. reported a CMS MIPS final score of 94.1036/100 — above the 83.1 national average — and filed 798 Medicare Part D claims in 2023.
- 94.1036/100
- MIPS score · +11 vs avg
- 798
- Part D claims, 2023
- 57%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
PADMINI KAUSHAL, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
94 Top 25% higher than 75% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
PADMINI KAUSHAL, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about PADMINI KAUSHAL, M.D.?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Illinois
How Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician compares to other specialties among Illinois providers
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician share within Illinois
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is one of the more visible NUCC categories in Illinois
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
PADMINI KAUSHAL, M.D.'s 2023 MIPS final score plotted against the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician national average
- MIPS Final Score
- 94.1036/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) — 94.1036/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician US NPIs
94.1036/100 MIPS final score — 11.0 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician. Quality dim: 82.5938.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
PADMINI KAUSHAL, M.D. appears in the CMS NPPES registry as a Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider holding M.D. credentials at 2015 N MAIN ST, WHEATON, IL, 60187, with a listed phone of (630) 668-8250. NPI 1801099288 was issued on 06/06/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what KAUSHAL most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 798 prescription claims written by this provider, covering 263 Medicare beneficiaries and totaling roughly $166K in drug spend, split 43% brand-name and 57% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 94.1036/100 for the 2023 performance year (Quality 82.5938), compared with the national average of 83.1.
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is a narrow specialty nationwide, with 37 enrolled providers across 15 states and an average of 642 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1801099288 |
|---|---|
| Specialty | Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 06/06/2007 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm PADMINI KAUSHAL, M.D.'s current license status, disciplinary history, and board certifications with the Illinois Department of Financial and Professional Regulation in Illinois before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Alternative Payment Model
Hospital and facility affiliations
Facilities where PADMINI KAUSHAL, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for PADMINI KAUSHAL, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$260
Largest payer
Bausch & Lomb Americas Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — Illinois IDFPR 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~42K Illinois medical licensees in 2023 — they are NOT specific to PADMINI KAUSHAL, M.D.. To verify PADMINI KAUSHAL, M.D.'s current license status, search the IDFPR public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
IDFPR publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Illinois disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
43% brand-name claims vs 57% generic, on 798 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,394
- Total Day Supply
- 39,057
- Brand vs Generic
- 43% brand / 57% generic
- Brand Drug Cost
- $149K
- Generic Drug Cost
- $18K
Patient Demographics
- Average Patient Age
- 74.7 years
- Avg HCC Risk Score
- 1.14
- Gender Split
- 69% female / 31% male
- Age Distribution
- <65: 16, 65-74: 116, 75-84: 99, 85+: 32
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What PADMINI KAUSHAL, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Latanoprost
Latanoprost
173 claims
- Restasis
Restasis
93 claims
- Valacyclovir 65
Valacyclovir
65 claims
- Prednisolone Acetate 61
Prednisolone Acetate
61 claims
- Dorzolamide-Timolol 56
Dorzolamide-Timolol
56 claims
- Prednisone 54
Prednisone
54 claims
- Erythromycin 49
Erythromycin
49 claims
- Neomycin-Polymyxin… 33
Neomycin-Polymyxin-Dexameth
33 claims
| Drug | Claims |
|---|---|
| Latanoprost | 173 |
| Restasis Cyclosporine | 93 |
| Valacyclovir Valacyclovir Hcl | 65 |
| Prednisolone Acetate | 61 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 56 |
| Prednisone | 54 |
| Erythromycin Erythromycin Base | 49 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 33 |
| Cequa Cyclosporine | 29 |
| Difluprednate | 29 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Overview
How PADMINI KAUSHAL, M.D. fits within the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician landscape nationally.
PADMINI KAUSHAL, M.D.'s 798 claims are above the specialty average of 642.
Nearby Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in Illinois
Other clinicians with the same primary specialty enrolled in Illinois, drawn from the same CMS NPPES roster as KAUSHAL.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Illinois
Frequently Asked Questions
What is PADMINI KAUSHAL, M.D.'s specialty? ▼
How much does PADMINI KAUSHAL, M.D. prescribe under Medicare Part D? ▼
What is PADMINI KAUSHAL, M.D.'s Medicare quality score? ▼
Where is PADMINI KAUSHAL, M.D. located? ▼
What is PADMINI KAUSHAL, M.D.'s NPI number? ▼
Does PADMINI KAUSHAL, M.D. prescribe more brand-name or generic drugs? ▼
How many Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers are there in the US? ▼
What drugs does PADMINI KAUSHAL, M.D. prescribe most often? ▼
Does PADMINI KAUSHAL, M.D. accept Medicare? ▼
How can I verify PADMINI KAUSHAL, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology